Elacestrant, the leading oral drug candidate designed to degrade the estrogen receptor, continues to show prolonged antitumor activity, according to data presented at the ESMO Congress 2022. But not all oral selective estrogen receptor degraders have demonstrated impressive efficacy. In August, Sanofi announced that it was ending development of amcenestrant after an interim analysis of a pivotal phase III trial found that the study would likely end in failure.

You do not currently have access to this content.